The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | SELECT-AML-1: tamibarotene with venetoclax and azacitidine in patients with RARA-positive AML
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explains the rationale and design of the SELECT-AML-1 trial (NCT04905407) evaluating the RARA agonist tamibarotene in combination with venetoclax and azacitidine in patients with RARA-positive acute myeloid leukemia (AML). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
